Guardant Health, Inc. (GH)
After hours:
| Previous close | 72.75 |
| Open | 71.89 |
| Bid | 68.68 x 800 |
| Ask | 77.31 x 900 |
| Day's range | 69.42 - 73.65 |
| 52-week range | 69.42 - 181.07 |
| Volume | |
| Avg. volume | 1,132,659 |
| Market cap | 7.126B |
| Beta (5Y monthly) | 0.45 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -4.05 |
| Earnings date | 22 Feb 2022 - 28 Feb 2022 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 166.75 |
- Zacks
After Plunging 27.6% in 4 Weeks, Here's Why the Trend Might Reverse for Guardant Health (GH)
Guardant Health (GH) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
- Business Wire
Guardant Health to Present Data Highlighting the Clinical Utility of Its Liquid Biopsy Tests in Gastrointestinal Cancers at ASCO GI Cancers Symposium
REDWOOD CITY, Calif., January 19, 2022--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will present data highlighting the clinical utility of its liquid biopsy tests in the treatment and management of early- to late-stage gastrointestinal cancers, including colorectal cancer, at the 2022 ASCO Gastrointestinal Cancers Symposium being held January 20-22, 2022.
- Business Wire
Guardant Health Enrolls First Patient in SHIELD LUNG Study to Evaluate Accuracy of Its Blood Test to Detect Lung Cancer in High-Risk Adults
REDWOOD CITY, Calif., January 18, 2022--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced today the enrollment of the first patient in the SHIELD (Screening for HIgh-frEquency maLignant Disease) LUNG study, a nearly 10,000-patient prospective, registrational study to evaluate the performance of its next-generation Guardant SHIELD blood test in detecting lung cancer in high-risk individuals ages 50-80. The study is anticipated to run in approximately 100 centers
